Said to offer the highest purity and most time and cost efficient chromatography media for the industrial purification of monoclonal antibodies (MAbs) on the market
GE Healthcare has announced the addition of two new products designed to meet growing industry needs for the purification of monoclonal antibodies (MAbs).
MabSelect Xtra and MabSelect Sure are said to offer customers the highest purity and most time and cost efficient chromatography media for the industrial purification of MAbs on the market.
"The success of monoclonal antibodies as therapeutics for the treatment of cancer and immunological diseases has driven the need for more time efficient and cost effective tools for the development and manufacturing of these antibodies on an industrial scale," said Peter Ehrenheim, president of protein separations at GE Healthcare, "GE Healthcare is committed to helping our customers handle larger volumes of higher titer feedstock while increasing yield to help reduce the overall cost of production.
"This will ultimately lead to the creation of promising new agents for human therapy".
Monoclonal antibodies are revolutionising the treatment of many illnesses and have become important cornerstones of modern medicine.
MAbs are antibodies of exceptional purity and specificity that are components of the immune system and are able to recognise and bind to a specific antigen.
MAbs are used in many diagnostic procedures and form the basis of many new therapeutic products.
MabSelect Xtra (extra capacity) is a new recombinant protein A-based chromatography medium that captures antibodies with improved efficiency and economy.
It is engineered to give 30% higher dynamic binding capacity than other commercially available protein A-based media.
This higher capacity translates directly into lower cost of production, especially when capturing antibodies from high-expression feedstocks.
MabSelect Sure (superior resistance) is a chromatography medium based on a novel alkali-stabilised protein A-derived ligand engineered to provide greater stability than conventional protein A-based media in the alkaline conditions used in cleaning-in-place (CIP) protocols.
The use of sodium hydroxide with MabSelect Sure means lower costs for cleaning and fewer failed batches.
The medium is ideal for regular production or in early clinical phases/process development.
